Cargando…
P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
Autores principales: | Hart, Kevin C., Santos, Daniel, Pandya, Deepal, Deng, Rong, LI, Keyu, Guan, Yinghui, Hernandez, Genevive, Manley, Thomas, Leabman, Maya K., Hinton, Paul R., Liu, Liqin, Sinclair, Angus M., Candia, Albert F., Carroll, Stephen F., Keyt, Bruce A., Kotturi, Maya F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430526/ http://dx.doi.org/10.1097/01.HS9.0000970164.63056.5c |
Ejemplares similares
-
P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
por: Leabman, M. K., et al.
Publicado: (2022) -
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
por: Wang, Beatrice T., et al.
Publicado: (2021) -
Structure, Function, and Therapeutic Use of IgM Antibodies
por: Keyt, Bruce A., et al.
Publicado: (2020) -
Pediatric Selective IgM Immunodeficiency
por: Goldstein, Marc F., et al.
Publicado: (2008) -
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
por: Zhang, Jingjing, et al.
Publicado: (2022)